Compare Brunswick Corporation (BC) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

BC trades at $80.43, down 1.37% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $1.56 versus $1.19 estimated, and the company maintains a dividend payout. Despite negative net income margins and ROE, revenue trends show stabilization, and cash flow from operations remains positive at $562.10M for 2025.

The outlook is cautiously optimistic, driven by earnings beats and a consensus price target of $85.33, but risks include persistent unprofitability and high debt levels. Investors may find opportunity in the bullish technical setup and institutional buying, though margin pressures and competitive challenges warrant close monitoring.

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.